

ASX Announcement

Medibio Limited – 12 April 2023

BOARD & MANAGEMENT CHANGES & CHANGE OF REGISTERED OFFICE & PPB

Melbourne, Australia and Minneapolis, MN – 12 April 2023: Medibio Limited (MEB or the Company) (ASX: MEB) (OTCPINK: MDBIF), is pleased to announce the appointment of Dr. Thomas Young as Executive Director of the Company in addition to his current position as Chief Executive Officer. There will be no changes to Tom's current remuneration structure previously announced.

Tom has demonstrated exceptional leadership skills and invaluable industry knowledge in his role as CEO during the short period and the Company looks forward to Tom leading the Company's management going forward.

The Company also announces the resignation of Ms Melanie Leydin as a Non-Executive Director of the Company.

The Company is also pleased to announce the appointment of Mr Stephen Buckley as Company Secretary. He will replace Mr Mathew Watkins, who has tendered his resignation as Company Secretary of the Company, both effective from 17 April 2023.

Melanie has been involved with the Company for an extended period in various capacities. The Company would like to extend its appreciation to Melanie and Mathew's leadership and guidance throughout their respective tenures.

Stephen Buckley is a director of Governance Corporate Pty Ltd, a company that provides specialised governance and company secretarial services to ASX listed companies. Stephen currently acts as Company Secretary for four other ASX listed entities.

Change of Registered Office and Principal Place of Business

In addition, the Company is also pleased to announce the change of the address of the Company's Registered Office and Principal Place of Business to 647 Beaufort Street, Mt Lawley WA 6050, with the phone number +61 8 6189 1155 .

In commenting on Board and management changes, David Trimboli, Non-Executive Chair of Medibio Limited said: *"We are excited to welcome Dr Tom Young onto the Medibio Board. Tom's executive position within the Company, his knowledge of the US industry and most importantly his proven track record in commercialising medical based technologies ensures the Board restructure at the Company is now complete and we can focus on developing our technology and commercialising.*

The Board would like to thank Melanie and Mathew for all of their work and cooperation during this restructuring process."

ENDS

This announcement is authorised for release to the market by the Board of Directors of Medibio Limited.

ASX Announcement

About Medibio Limited

Medibio (ASX: MEB) (OTCQB: MDBIF) is a mental health technology company pioneering the use of objective measures to aid in the early detection and screening of mental health conditions. Through their Corporate Health product, the Company offers mental well-being solutions for businesses and are also developing products to serve the healthcare provider market. The Company was founded in Australia, with offices located in Melbourne (Vic) and Minneapolis (MN). Medibio is listed on the Australian Securities Exchange Ltd and trades on the OTCQB Venture Market. Investors can find additional information on www.otcmarkets.com and www.asx.com.au.

For Further information:

David Trimboli

Non-Executive Chair

investors@medibio.com.au

+61 8 6189 1155